NORTH CHICAGO, Ill., April 17, 2023 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved expanding the indication of Qulipta (atogepant) for the preventive treatment of migraine
U.S. FDA Approves Qulipta (atogepant) for Adults With Chronic Migraine
